Literature DB >> 20048702

Fc receptor-mediated antiviral antibodies.

Donald N Forthal1, Christiane Moog.   

Abstract

PURPOSE OF REVIEW: We summarize current information on Fc receptor-mediated antiviral activities of antibodies. These activities include Fcgamma receptor-mediated inhibition and neutralization of HIV on antigen-presenting cells, antibody-dependent cellular cytotoxicity, and antibody-dependent cell-mediated virus inhibition (ADCVI). RECENT
FINDINGS: An Fcgamma receptor-mediated mechanism that results in augmented neutralization and may render nonneutralizing antibodies inhibitory has been demonstrated in antigen-presenting cell. Antibody-dependent cellular cytotoxicity antibody activity correlates inversely with HIV disease progression in humans, and higher vaccine-induced antibody-dependent cellular cytotoxicity antibody responses are associated with lower acute simian immunodeficiency virus viremia levels in macaques. Following vaccination with rgp120, ADCVI antibody levels are higher among those with a lower rate of sexually acquired HIV infection. Nonneutralizing simian immunodeficiency virus immune serum that prevents infection of newborn macaques after oral challenge has potent ADCVI antibody activity. Abrogating the ability of the Fc segment of the broadly neutralizing mAb b12 to bind to Fcgamma receptors and to mediate ADCVI substantially reduces b12's protective effect in a simian/human immunodeficiency virus vaginal challenge model.
SUMMARY: Fc-FcgammaR interactions play a critical role in the biological function of antibody and are likely to be instrumental in preventing or modulating lentiviral infection. Exploiting antibody responses that depend on Fc-FcgammaR interactions may help widen the breadth and increase the potency of vaccine-induced antibody. Although the importance of generating optimal Fab-antigen interactions cannot be overestimated, improving Fc-FcgammaR interactions through adjuvants or other strategies provides another option for improving HIV vaccines and immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20048702      PMCID: PMC2882066          DOI: 10.1097/COH.0b013e32832f0a89

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  49 in total

Review 1.  Roles of Fc receptors in autoimmunity.

Authors:  Toshiyuki Takai
Journal:  Nat Rev Immunol       Date:  2002-08       Impact factor: 53.106

2.  Studies on the association of Fc gamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A.

Authors:  C Kyogoku; N Tsuchiya; K Matsuta; K Tokunaga
Journal:  Genes Immun       Date:  2002-12       Impact factor: 2.676

3.  Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus.

Authors:  K E Sullivan; A F Jawad; L M Piliero; N Kim; X Luan; D Goldman; M Petri
Journal:  Rheumatology (Oxford)       Date:  2003-03       Impact factor: 7.580

4.  Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.

Authors:  A H Rook; H C Lane; T Folks; S McCoy; H Alter; A S Fauci
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

5.  Evidence for non-random distribution of Fcgamma receptor genotype combinations.

Authors:  W-Ludo van der Pol; Marc D Jansen; Wim J Sluiter; Bart van de Sluis; Fredriek G J Leppers-van de Straat; Tetsuo Kobayashi; Rudi G J Westendorp; Tom W J Huizinga; Jan G J van de Winkel
Journal:  Immunogenetics       Date:  2003-06-26       Impact factor: 2.846

6.  Polymorphism of Fc receptor IIa for immunoglobulin G is associated with placental malaria in HIV-1-positive women in western Kenya.

Authors:  Kimberly C Brouwer; Altaf A Lal; Lisa B Mirel; Juliana Otieno; John Ayisi; Anne M Van Eijk; Renu B Lal; Richard Steketee; Bernard L Nahlen; Ya Ping Shi
Journal:  J Infect Dis       Date:  2004-08-17       Impact factor: 5.226

7.  Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Authors:  Lautaro G Perez; Matthew R Costa; Christopher A Todd; Barton F Haynes; David C Montefiori
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

8.  Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface.

Authors:  Takeshi Yamada; Nobukazu Watanabe; Tetsuya Nakamura; Aikichi Iwamoto
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

Review 9.  FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

Authors:  N M van Sorge; W-L van der Pol; J G J van de Winkel
Journal:  Tissue Antigens       Date:  2003-03

10.  Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages.

Authors:  K Ljunggren; B Böttiger; G Biberfeld; A Karlson; E M Fenyö; M Jondal
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

View more
  76 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

4.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

5.  Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.

Authors:  Julie F Weis; R Scott McClelland; Walter Jaoko; Kishor N Mandaliya; Julie Overbaugh; Susan M Graham
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-13       Impact factor: 2.205

6.  Challenges of antibody-mediated protection against HIV-1.

Authors:  George K Lewis
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

7.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

8.  Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Peng Xiao; Jun Zhao; L Jean Patterson; Egidio Brocca-Cofano; David Venzon; Pamela A Kozlowski; Rachmat Hidajat; Thorsten Demberg; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

9.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

10.  Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.

Authors:  Susan Zolla-Pazner
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.